S
Sebastian Cummins
Researcher at Royal Surrey County Hospital
Publications - 15
Citations - 2215
Sebastian Cummins is an academic researcher from Royal Surrey County Hospital. The author has contributed to research in topics: Capecitabine & Gemcitabine. The author has an hindex of 8, co-authored 15 publications receiving 1601 citations. Previous affiliations of Sebastian Cummins include National Institute for Health Research.
Papers
More filters
Journal ArticleDOI
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos,John P. Neoptolemos,Daniel H. Palmer,Daniel H. Palmer,Paula Ghaneh,Eftychia E. Psarelli,Juan W. Valle,Christopher Halloran,Christopher Halloran,Olusola Olusesan Faluyi,Derek A. O'Reilly,David Cunningham,Jonathan Wadsley,Suzanne Darby,Tim Meyer,Roopinder Gillmore,Alan Anthoney,Pehr Lind,Bengt Glimelius,Stephen Falk,Jakob R. Izbicki,Gary Middleton,Sebastian Cummins,Paul Ross,Harpreet Wasan,Alec McDonald,Tom Crosby,Yuk Ting Ma,Kinnari Patel,David Sherriff,Rubin Soomal,David Borg,Sharmila Sothi,Pascal Hammel,Thilo Hackert,Richard J. Jackson,Markus W. Büchler +36 more
TL;DR: The adjuvant combination of gem citabine and capecitabine should be the new standard of care following resection for pancreatic ductal adenocarcinoma.
Journal ArticleDOI
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial
Somnath Mukherjee,Chris Nicholas Hurt,John Bridgewater,Stephen Falk,Sebastian Cummins,Harpreet Wasan,Thomas Crosby,Catherine Jephcott,Rajarshi Roy,Ganesh Radhakrishna,Alec McDonald,Ruby Ray,George Joseph,John Staffurth,John Staffurth,Ross A. Abrams,Gareth Griffiths,Gareth Griffiths,Tim Maughan +18 more
TL;DR: This open-label, randomised, two-arm, phase 2 trial aimed to assess the activity, safety, and feasibility of both gemcitabine-based and capecitabines-based chemoradiotherapy after induction chemotherapy for patients with locally advanced pancreatic cancer.
Journal ArticleDOI
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
Harpreet Wasan,Peter Gibbs,Navesh K Sharma,Julien Taieb,Volker Heinemann,Jens Ricke,Marc Peeters,Michael Findlay,Andrew Weaver,Jamie Mills,Charles Wilson,Richard Adams,Anne Francis,Joanna Moschandreas,P S Virdee,Peter Dutton,Sharon Love,Val Gebski,Alastair Gray,Andrew Bateman,Claire Blesing,Ewan Brown,Ian Chau,Sebastian Cummins,David Cunningham,Stephen Falk,Maher Hadaki,Marcia Hall,Tamas Hickish,Joanne Hornbuckle,F. Lofts,Sarah Lowndes,Astrid Mayer,Matthew Metcalfe,Gary Middleton,Amir Montazeri,Rebecca Muirhead,Andreas Polychronis,Colin Purcell,Paul Ross,Ricky A. Sharma,Liz Sherwin,David J. Smith,Rubin Soomal,Daniel Swinson,Axel Walther,Harpreet Wasan,Greg Wilson,Pradip Amin,Bruna Angelelli,Jacques Balosso,Alex Beny,Daniel Bloomgarden,Evelyn Boucher,Michael P. Brown,Harald-Robert Bruch,James Bui,Matthew Burge,Giuseppe Cardaci,James Carlisle,Seungjean Chai,Yi-Jen Chen,Patrick Chevallier,Michael Chuong,Stephen Clarke,Andrew L. Coveler,Michael Craninx,Thierry Delanoit,Amélie Deleporte,Paul Eliadis,Francis Facchini,Tom Ferguson,Michel Ferrante,Gary Frenette,Jacob Frick,Vinod Ganju,Michael Garofalo,Karen Geboes,Gerald Gehbauer,Benjamin George,Ravit Geva,Michael Gordon,Kate Gregory,Seza Gulec,James Hannigan,Guy van Hazel,Norman Isaac Heching,Thomas Helmberger,Alain Hendlisz,Koen Hendrickx,Matthew Holtzman,Richard Isaacs,Christopher Jackson,Philip T. James,Adeel Kaiser,Chris Karapetis,Andreas Kaubisch,Yon-Dschun Ko,H. Kröning,Frank Lammert,Winston Liauw,Steven Limentani,Samy Louafi,Marc De Man,Jeffrey Margolis,Robert C.G. Martin,Andrea Martoni,Gavin Marx,Marco Matos,E Monsaert,Veerle Moons,Louise M. Nott,Arnd Nusch,Anne O'Donnell,Howard Ozer,Siddarth A Padia,Nick Pavlakis,David Perez,Stefan Pluntke,Marc Polus,Alex Powell,Marc Pracht,Timothy J. Price,David Ransom,Christine Rebischung,Karsten Ridwelski,Jorge Riera-Knorrenschild,Hanno Riess,William S. Rilling,Bridget A. Robinson,Javier Rodríguez,Federico Sanchez,Tilmann Sauerbruch,Michael Savin,Klemens Scheidhauer,Elyse Schneiderman,Grant Seeger,Eva Segelov,Einat Shaham Schmueli,Adi Shani,Jenny Shannon,Navesh K. Sharma,Stephen Shibata,Nimit Singhal,Denis Smith,Randall Smith,Salomon M. Stemmer,Oliver Stötzer,Andrew Strickland,Klaus Tatsch,Eric Terrebonne,Thomas Tichler,Ursula Vehling-Kaiser,Ruth Vera-Garcia,Thomas J Vogl,Euan Walpole,Eric Wang,Samuel Whiting,Ido Wolf,Steven Ades,Morteza Aghmesheh,Miklos Auber,Hubert Ayala,Patrick McKay Boland,Eveline Bouche,Charles Bowers,Christoph Bremer,M. Burge,Ana Ruíz Casado,Prasad Cooray,Martin R. Crain,Maike De Wit,Kyran Dowling,Aurelie Durand,Sandrine Faivre,Kynan Feeney,Thomas W. Ferguson,Aurelie Ferru,Maria Fragoso,Cristina Granetto,Pascal Hammel,Richard Issacs,Renuka Iyer,Yeul Hong Kim,Jin-Tung Liang,Lionel Lim,Jin Hwang Liu,Gianluca Masi,Stefania Mosconi,Gianmauro Numico,Lynn Ratner,Han Sae-Won,Madhu Sudan Singh,Patricia Stoltzfus,Iain Tan,Antonio Trogu,Craig Underhill,Mark Westcott +197 more
TL;DR: Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit in patients with coloreCTal liver metastases with liver-dominant disease after chemotherapy.
Journal ArticleDOI
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial
Robert P. Jones,Eftychia-Eirini Psarelli,Richard J. Jackson,Paula Ghaneh,Paula Ghaneh,Christopher Halloran,Christopher Halloran,Daniel H. Palmer,Daniel H. Palmer,Fiona Campbell,Juan W. Valle,Olusola Olusesan Faluyi,Derek A. O'Reilly,David Cunningham,Jonathan Wadsley,Suzanne Darby,Tim Meyer,Roopinder Gillmore,Alan Anthoney,Pehr Lind,Bengt Glimelius,Stephen Falk,Jakob R. Izbicki,Gary Middleton,Sebastian Cummins,Paul Ross,Harpreet Wasan,Alec McDonald,Tom Crosby,Yuk Ting,Kinnari Patel,David Sherriff,Rubin Soomal,David Borg,Sharmila Sothi,Pascal Hammel,Markus M. Lerch,Julia Mayerle,Julia Mayerle,Christine Tjaden,Oliver Strobel,Thilo Hackert,Markus W. Büchler,John P. Neoptolemos +43 more
TL;DR: There were no significant differences between the time to recurrence and subsequent and overall survival between local and distant recurrence in patients who had resection and adjuvant chemotherapy for pancreatic cancer.
Journal ArticleDOI
Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial.
Peter Hall,Peter Hall,Daniel Swinson,David A Cairns,Justin S. Waters,Russell D Petty,Christine Allmark,Sharon Ruddock,Stephen Falk,Jonathan Wadsley,Rajarshi Roy,Tania Tillett,Jonathan Nicoll,Sebastian Cummins,Joseph Mano,Simon Aird Grumett,Zuzana Stokes,Kamposioras Konstantinos-Velios,Anirban Chatterjee,Angel Garcia,Tom Samuel Waddell,Kamalnayan Guptal,Nick Maisey,Mohammed Khan,Jo Dent,Simon Lord,Ann Crossley,Eszter Katona,Helen Marshall,Heike I. Grabsch,Heike I. Grabsch,Galina Velikova,Pei Loo Ow,C. Handforth,Helen Howard,Matthew T. Seymour,Matthew T. Seymour,Go Trial Investigators,Go Trial Investigators,Eleanor James,Sue Cheeseman,Tom Roques,Nicholas S. Reed,Charles Candish,D. Fyfe,Richard Ellis,Lesley Samuel,Rebecca Herbertson,Louise Medley,Kinnari Patel,David Sherriff,A. Robinson,Pavel Bezecny,Dunca Wilkins,Adam McGeoch,Daniel Propper,Olwyn Williams,Serena Hilman,Sherif Raouf,Claire Hobbs,Jo Parkinson,Nick Wadd,W Saku,Victori Kunene,Colin Askill,Arshad Jamil,Emma Cattell,Lauren Gorf,Vallipuram Vigneswaran,Erica Beaumont,Syed Zubair,Elin Jones,Nicholas Reed,Alaaeldin Shablak,George Bozas,Sheela Rao,Michael Bennet,Joanne Askey,Gareth Griffiths,Sally Clive,Vanessa Potter,Jean Gall,Chris Twelves,Matthew R. Sydes,Juan W. Valle,Jo Webster,Marc Jones,Fiona Collinson,Julia Brown,Louise Brook +89 more
TL;DR: The CHEMO-INTENSITY randomized clinical trial as discussed by the authors found that reduced-intensity chemotherapy provided a better patient experience without significantly compromising cancer control and should be considered for older and/or frail patients.